| Literature DB >> 33287422 |
Jürgen Prasch1, Eva Bernhart1, Helga Reicher1, Manfred Kollroser2, Gerald N Rechberger3,4, Chintan N Koyani1,5, Christopher Trummer1, Lavinia Rech5, Peter P Rainer5, Astrid Hammer6, Ernst Malle1, Wolfgang Sattler1,4.
Abstract
Sepsis is a major cause of mortality in critically ill patients and associated with cardiac dysfunction, a complication linked to immunological and metabolic aberrations. Cardiac neutrophil infiltration and subsequent release of myeloperoxidase (MPO) leads to the formation of the oxidant hypochlorous acid (HOCl) that is able to chemically modify plasmalogens (ether-phospholipids) abundantly present in the heart. This reaction gives rise to the formation of reactive lipid species including aldehydes and chlorinated fatty acids. During the present study, we tested whether endotoxemia increases MPO-dependent lipid oxidation/modification in the mouse heart. In hearts of lipopolysaccharide-injected mice, we observed significantly higher infiltration of MPO-positive cells, increased fatty acid content, and formation of 2-chlorohexadecanal (2-ClHDA), an MPO-derived plasmalogen modification product. Using murine HL-1 cardiomyocytes as in vitro model, we show that exogenously added HOCl attacks the cellular plasmalogen pool and gives rise to the formation of 2-ClHDA. Addition of 2-ClHDA to HL-1 cardiomyocytes resulted in conversion to 2-chlorohexadecanoic acid and 2-chlorohexadecanol, indicating fatty aldehyde dehydrogenase-mediated redox metabolism. However, a recovery of only 40% indicated the formation of non-extractable (protein) adducts. To identify protein targets, we used a clickable alkynyl analog, 2-chlorohexadec-15-yn-1-al (2-ClHDyA). After Huisgen 1,3-dipolar cycloaddition of 5-tetramethylrhodamine azide (N3-TAMRA) and two dimensional-gel electrophoresis (2D-GE), we were able to identify 51 proteins that form adducts with 2-ClHDyA. Gene ontology enrichment analyses revealed an overrepresentation of heat shock and chaperone, energy metabolism, and cytoskeletal proteins as major targets. Our observations in a murine endotoxemia model demonstrate formation of HOCl-modified lipids in the heart, while pathway analysis in vitro revealed that the chlorinated aldehyde targets specific protein subsets, which are central to cardiac function.Entities:
Keywords: click chemistry; electrophile damage; fatty acids; hypochlorous acid; myeloperoxidase; proteomics
Year: 2020 PMID: 33287422 PMCID: PMC7730634 DOI: 10.3390/ijms21239235
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Immunohistochemical analysis of MPO expression in hearts of PBS- and LPS-treated mice. C57BL/6 mice received a single i.p. injection of PBS (200 µL) or LPS in PBS (from Escherichia coli, 0111:B4 in PBS, 8 µg/g body weight) and were sacrificed 12 h after the injection. (A) Representative MPO-immunostainings of hearts isolated from PBS- and LPS-injected animals are shown at low and high magnification. (B) Statistical evaluation of MPO-positive cells in the sections of the hearts of PBS- or LPS-injected mice. Cryosections of eight different heart regions from PBS- or LPS-injected animals (n = 3) were counted manually for MPO-positive cells. Lines indicate mean ± SD values. Unpaired student’s t-test; **** p ≤ 0.0001.
Figure 2Accumulation of various fatty acid (FA) species and 2-ClHDA in LPS-treated hearts. C57BL/6 mice received a single i.p. injection of PBS (200 µ) or LPS in PBS (from Escherichia coli, 0111:B4 in PBS, 8 µg/g body weight) and were sacrificed 8 or 12 h after the injection. (A) Cardiac FA composition of PBS- and LPS-injected mice was analyzed by gas chromatography. Inset shows total FA concentrations. Data represent mean + SEM; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; unpaired student’s t-test (n = 5–6). (B–D) Cardiac 2-ClHDA concentrations were quantified by selected ion monitoring (SIM) NICI–GC–MS analysis using 2-Cl[13C8]HDA as internal standard. (B) SIM chromatograms of a representative cardiac lipid sample (top; 12 h post LPS treatment) and the synthetic standard (bottom). Boxed areas indicate the elution profiles of the syn- and anti-PFB-oxime derivatives of 2-ClHDA and 2-Cl[13C8]HDA. (C) Fragment ion intensity ratios of 2-ClHDA (m/z = 288, 290) and the internal standard (m/z = 296, 298) of the peaks highlighted in (B). (D) Formation of 2-ClHDA in the hearts of LPS-treated animals (n = 6) measured 12 h after a single systemic LPS injection. Lines represent median with interquartile range, unpaired student‘s t-test, non-detectable (n.d.).
Figure 3In vitro formation and metabolism of 2-ClHDA in the murine HL-1 cardiomyocyte cell line. HL-1 cells were incubated with increasing concentrations of NaOCl or 2-ClHDA (15 µM). (A) After treatment with indicated concentrations of NaOCl for 1 h, cells were extracted in the presence of the corresponding internal standard as outlined in Materials and Methods. After conversion to their corresponding PFB-derivatives, 2-ClHDA, 2-ClHA, and 2-ClHOH concentrations were quantitated by NICI-GC–MS analysis. Results are displayed as mean ± SD (n = 3). (B,C) Cells were incubated with 15 µM 2-ClHDA for up to 4 h. At the indicated time points, 2-ClHDA, 2-ClHA, and 2-ClHOH concentrations were analyzed by NICI-GC–MS analysis in (B) the cellular supernatants and (C) HL-1 cells. Data represent mean ± SD values (n = 3). (D) Time-dependent recovery of 2-Cl-metabolites in HL-1 cells. Data represent loss of 2-ClHDA from the supernatant (SN), recovery of 2-Cl-Analytes (sum of 2-ClHDA, 2-ClHA, and 2-ClHOH in the SN or cells), and recovery of 2-ClHA plus 2-ClHOH in the supernatant (for reasons of clarity only mean values are shown).
Figure 4Effects of 2-ClHDA and 2-ClHDyA on cell viability. Viability of HL-1 cells was assessed with the CellTiter-Glo 3D kit detecting ATP as an indicator of cell viability. Cells were treated with (A) 2-ClHDA or (B) 2-ClHDyA at indicated concentrations for 30 min and 24 h. The time-dependent effect of 50 µM 2-ClHDA and 2-ClHDyA on cell viability is shown in (C) and (D), respectively. DMSO was used as vehicle control. Data represent mean ± SD values (n = 3).
Figure 5Adduct formation of 2-ClHDyA with cardiac proteins. (A) HL-1 cells were incubated in the absence (‘-‘) or presence (‘+’) of 50 µM 2-ClHDyA for the indicated time points (left panel) or with 10, 20, and 50 µM 2-ClHDyA for 30 min (right panel). 10-Undecyn-1-ol served as a negative control. Cell lysates were subjected to click chemistry with N3-TAMRA, separated by SDS-PAGE, and imaged using a Typhoon 9400 scanner (upper panel). Coomassie Brilliant Blue staining was performed to verify equal protein loading (lower panel). (B) Time- and (C) concentration-dependent increase in fluorescence intensities normalized to overall protein intensity/lane from the gels shown in (A). One representative experiment is shown.
2-ClHDyA-modified proteins identified in whole cell lysates of HL-1 cardiomyocytes. Only proteins identified in two out of three gels are displayed.
| Uniprot ID | Short Name | Group | Full Name | Molecular Mass (Da) | Isoelectric Point (pI) |
|---|---|---|---|---|---|
| Q8BFZ3 | Actbl2 | Beta-actin-like protein 2 | 42,345.8 | 5.31 | |
| Q99KJ8 | Dctn2 | Dynactin subunit 2 | 44,230.2 | 5.14 | |
| P31001 | Des | Desmin | 53,553.9 | 5.21 | |
| P48678 | Lmna | Prelamin-A/C | 74,521.5 | 6.54 | |
| P15331 | Prph | Peripherin | 54,380.8 | 5.40 | |
| P14206 | Rpsa | 40S ribosomal protein SA | 32,951.6 | 4.80 | |
| P05214 | Tuba3b | Tubulin alpha-3 chain | 50,643.3 | 4.98 | |
| Q3UX10 | Tubal3 | Tubulin alpha chain-like 3 | 50,728.9 | 5.37 | |
| Q9ERD7 | Tubb3 | Tubulin beta-3 chain | 50,874.2 | 4.82 | |
| Q922F4 | Tubb6 | Tubulin beta-6 chain | 50,545.9 | 4.80 | |
| P20152 | Vim | Vimentin | 53,743.8 | 5.06 | |
| Q9CQV8 | Ywhab | 14-3-3 protein beta/alpha | 28,200.0 | 4.77 | |
| P80318 | Cct3 | T-complex protein 1 subunit gamma | 61,199.5 | 6.28 | |
| P80316 | Cct5 | T-complex protein 1 subunit epsilon | 60,079.5 | 5.72 | |
| P42932 | Cct8 | T-complex protein 1 subunit theta | 60,125.0 | 5.44 | |
| P62737 | Eif3f | Eukaryotic translation initiation factor 3 subunit F | 38,097.7 | 5.33 | |
| P10630 | Eif4a2 | Eukaryotic initiation factor 4A-II | 46,629.7 | 5.33 | |
| P30416 | Fkbp4 | Peptidyl-prolyl cis-trans isomerase FKBP4 | 51,970.8 | 5.54 | |
| P07901 | Hsp90aa1 | Heat shock protein HSP 90-alpha | 85,185.7 | 4.93 | |
| P16627 | Hspa1l | Heat shock 70 kDa protein 1-like | 71,035.4 | 5.91 | |
| P14602 | Hspb1 | Heat shock protein beta-1 | 23,070.5 | 6.12 | |
| P27773 | Pdia3 | Protein disulfide-isomerase A3 | 57,133.7 | 5.88 | |
| Q922R8 | Pdia6 | Protein disulfide-isomerase A6 | 38,097.7 | 5.33 | |
| Q9WVJ2 | Psmd13 | 26S proteasome non-ATPase regulatory subunit 13 | 43,150.9 | 5.46 | |
| Q60864 | Stip1 | Stress-induced-phosphoprotein 1 | 63,208.6 | 6.41 | |
| P11983 | Tcp1 | T-complex protein 1 subunit alpha | 60,904.0 | 5.82 | |
| P10518 | Alad | Delta-aminolevulinic acid dehydratase | 36,479.3 | 6.32 | |
| P47738 | Aldh2 | Aldehyde dehydrogenase, mitochondrial | 57,050.0 | 7.76 | |
| P05064 | Aldoa | Fructose-bisphosphate aldolase A | 39,811.6 | 8.75 | |
| P17182 | Eno1 | Alpha-enolase | 47,482.3 | 6.37 | |
| P16858 | Gapdh | Glyceraldehyde-3-phosphate dehydrogenase | 36,094.6 | 8.76 | |
| Q9D6R2 | Idh3a | Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial | 40,094.5 | 6.27 | |
| P06151 | Ldha | L-lactate dehydrogenase A chain | 36,840.2 | 7.84 | |
| Q91WD5 | Ndufs2 | NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, mitochondrial | 53,024.1 | 6.52 | |
| Q9DBJ1 | Pgam1 | Phosphoglycerate mutase 1 | 28,945.6 | 6.68 | |
| Q61753 | Phgdh | D-3-phosphoglycerate dehydrogenase | 57,383.3 | 6.12 | |
| Q9CZ13 | Uqcrc1 | Cytochrome b-c1 complex subunit 1, mitochondrial | 53,478.4 | 5.81 | |
| Q9DB77 | Uqcrc2 | Cytochrome b-c1 complex subunit 2, mitochondrial | 48,291.1 | 9.31 | |
| P07724 | Alb | Albumin | 70,745.2 | 5.75 | |
| Q9Z1Q5 | Clic1 | Chloride intracellular channel protein 1 | 27,354.6 | 5.09 | |
| Q8VDW0 | Ddx39 | ATP-dependent RNA helicase DDX39A | 49,580.0 | 5.46 | |
| Q9Z1N5 | Ddx39b | Spliceosome RNA helicase Ddx39b | 49,491.0 | 5.44 | |
| Q9D8N0 | Eef1g | Elongation factor 1-gamma | 50,402.1 | 6.31 | |
| P58252 | Eef2 | Elongation factor 2 | 96,282.3 | 6.41 | |
| Q920E5 | Fdps | Farnesyl pyrophosphate synthase | 40,923.1 | 5.49 | |
| Q8R081 | Hnrnpl | Heterogeneous nuclear ribonucleoprotein L | 64,590.1 | 8.75 | |
| P17897 | Lyz1 | Lysozyme C-1 | 17,250.3 | 10.35 | |
| P17918 | Pcna | Proliferating cell nuclear antigen | 29,126.7 | 4.66 | |
| Q91VI7 | Rnh1 | Ribonuclease inhibitor | 51,527.2 | 4.69 | |
| Q9WTM5 | Ruvbl2 | RuvB-like 2 | 51,282.8 | 5.49 | |
| Q3TW96 | Uap1l1 | UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 | 57,354.4 | 5.27 |
Blue group: Cytoskeleton; Red Group: Chaperones & Stress Response; Green group: Energy Metabolism; Grey Group: Miscellaneous.
Figure 6Specific network analysis of HL-1 proteins modified by 2-ClHDyA.
Characteristic m/z values used to identify and quantify chlorinated analytes.
| Analyte |
| Internal Standard |
| I.S. |
|---|---|---|---|---|
|
| 288/290 | 2-Cl[13C8]HDA | 296/298 | 1000 |
|
| 289/291 | 2-Cl[13C8]HA | 297/299 | 1000 |
|
| 470/472 | pentadecanol | 422 | 1000 |